Literature DB >> 17901981

siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells.

Jian Niu1, Xiang-Nong Li, Haixin Qian, Zeguang Han.   

Abstract

PURPOSE: This study was to investigate if downregulation of IGF1R and EGFR by RNA interference (RNAi) would sensitize human liver cancer cells (HEPG2, Huh7 ) to adriamycin.
METHODS: HEPG2, Huh7 cell lines were transfected IGF1R siRNAs and EGFR siRNAs and IGF1R or EGFR mRNA level was determined by RT-PCR and Western-blot analysis. We investigated the effects of the adriamycin-induced apoptosis of these cells by TUNEL assay. Also we analyze caspase3, 8 and the phosphorylation levels of Akt and Erk by Western-blot. The p53 effect of adriamycin-induced cell death by inhibitors of EGFR/IGF1R is investigated by cell growth curves.
RESULTS: Transfection of an IGF1R and EGFR siRNAs resulted in substantial loss of IGF1R and EGFR mRNA of HEPG2, Huh7 cells relative to the control case. EGFR siRNA and IGF1R siRNA treatments increased the adriamycin-induced apoptosis of these cells. IGF1R siRNA and EGFR siRNA enhance a caspase-dependent cell death program. The phosphorylation levels of Akt and Erk were reduced by the combination of the two agents. The facilitation of adriamycin-induced cell death by inhibitors of EGFR/IGF1R is p53-independent.
CONCLUSIONS: The results indicate that the siRNA for IGF1R has a great potential for cancer therapy when combined with either a chemotherapeutic agent or siRNAs that targets EGFR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17901981     DOI: 10.1007/s00432-007-0314-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  55 in total

1.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.

Authors:  T Putz; Z Culig; I E Eder; C Nessler-Menardi; G Bartsch; H Grunicke; F Uberall; H Klocker
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

Review 3.  Role of the insulin-like growth factor family in cancer development and progression.

Authors:  H Yu; T Rohan
Journal:  J Natl Cancer Inst       Date:  2000-09-20       Impact factor: 13.506

4.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Authors:  F M Sirotnak; M F Zakowski; V A Miller; H I Scher; M G Kris
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

Review 5.  The EGF receptor family as targets for cancer therapy.

Authors:  J Mendelsohn; J Baselga
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

6.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

7.  Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

Authors:  Dan Lu; Haifan Zhang; Dale Ludwig; Anita Persaud; Xenia Jimenez; Douglas Burtrum; Paul Balderes; Meilin Liu; Peter Bohlen; Larry Witte; Zhenping Zhu
Journal:  J Biol Chem       Date:  2003-10-23       Impact factor: 5.157

8.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

Authors:  Roberto Bianco; Incheol Shin; Christoph A Ritter; F Michael Yakes; Andrea Basso; Neal Rosen; Junji Tsurutani; Phillip A Dennis; Gordon B Mills; Carlos L Arteaga
Journal:  Oncogene       Date:  2003-05-08       Impact factor: 9.867

9.  Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop.

Authors:  J M Connolly; D P Rose
Journal:  Prostate       Date:  1994-04       Impact factor: 4.104

10.  Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells.

Authors:  Anne Camirand; Mahvash Zakikhani; Fiona Young; Michael Pollak
Journal:  Breast Cancer Res       Date:  2005-04-12       Impact factor: 6.466

View more
  5 in total

1.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

Review 2.  EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.

Authors:  Cristina Zahonero; Pilar Sánchez-Gómez
Journal:  Cell Mol Life Sci       Date:  2014-03-27       Impact factor: 9.261

3.  Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro.

Authors:  Ashraf Khalil; Mark J Jameson
Journal:  Horm Cancer       Date:  2018-10-23       Impact factor: 3.869

4.  Systemic siRNA Nanoparticle-Based Drugs Combined with Radiofrequency Ablation for Cancer Therapy.

Authors:  Muneeb Ahmed; Gaurav Kumar; Gemma Navarro; Yuanguo Wang; Svetlana Gourevitch; Marwan H Moussa; Nir Rozenblum; Tatyana Levchenko; Eithan Galun; Vladimir P Torchilin; S Nahum Goldberg
Journal:  PLoS One       Date:  2015-07-08       Impact factor: 3.240

5.  Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer.

Authors:  Jian Niu; Yue Wang; Ji Wang; Liu Bin; Xin Hu
Journal:  Aging (Albany NY)       Date:  2016-12-28       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.